GI & Hepatic Drugs PNLE Questions

Introduction

This page covers 19 original PNLE-style practice questions in the live Tangerine inventory for GI & Hepatic Drugs. The published inventory was last updated August 12, 2026. Use the set to test medication administration, expected effects, adverse-effect recognition, interactions, and prioritization.

GI & Hepatic Drugs is an NP7 Pharmacology practice lens covering acid-control, antiemetic, bowel, and hepatic medications. The decisions include matching a drug with its timing and formulation, checking renal or hepatic considerations, identifying unsafe combinations, distinguishing expected effects from complications, and selecting the safest nursing action. Diabetes and endocrine therapy are outside this topic and belong in Endocrine & Metabolic Drugs.

Under the 2025 Enhanced TOS, this lens is mapped across relevant competencies in the official five-subject PNLE TOS. It is not a separate official test subject, and the TOS does not assign a guaranteed microtopic count to GI & Hepatic Drugs. Use this page to strengthen pharmacology decisions within broader nursing competencies.

Key concepts

• Match acid-control therapy to the administration plan
  Recognize: Antacids, H2 blockers, and other acid-control medicines differ in timing, formulation, and interaction potential. Symptoms alone do not establish that every product can be substituted.
  Decide: Check the prescribed schedule, meal relationship, formulation instructions, and the patient’s other oral medicines before giving the dose.
  Avoid: Giving an antacid at the same time as every other oral drug or assuming an acid-control class is interchangeable.
• Use kidney status when evaluating acid-control safety
  Recognize: Chronic kidney disease can change medication clearance or increase concern with some agents, while warfarin adds an interaction and monitoring question.
  Decide: Review the medication profile, available renal information, ordered dose, and monitoring plan; clarify an unsafe or incomplete order.
  Avoid: Choosing a drug based only on symptom relief or treating all H2 blockers as identical in a patient with CKD and warfarin therapy.
• Interpret magnesium- and aluminum-based antacid effects
  Recognize: Magnesium-based products can produce loose stools, while aluminum-based products can contribute to constipation. Renal impairment makes product selection and monitoring more important.
  Decide: Correlate the bowel change with the medication, assess hydration and renal status, and follow the ordered plan for adjustment or referral.
  Avoid: Mistaking an expected bowel effect for treatment failure, or dismissing persistent symptoms without assessment.
• Screen for antiemetic-related CNS and movement problems
  Recognize: Metoclopramide may cause drowsiness or abnormal movements, and CNS depressants can increase safety concerns.
  Decide: Assess level of consciousness, respiratory safety, fall risk, and new involuntary movements before and after administration; report concerning findings promptly.
  Avoid: Treating sedation as harmless or administering a potentially additive combination without reviewing the complete medication list.
• Judge lactulose by the hepatic response and the patient’s tolerance
  Recognize: In hepatic encephalopathy, an expected response includes increased bowel elimination with improved mental status. Excessive stooling may create dehydration or electrolyte concerns.
  Decide: Monitor mentation, stool pattern, hydration, and relevant laboratory information, then follow the individualized order or protocol.
  Avoid: Using stool frequency alone as the endpoint or allowing uncontrolled diarrhea to continue without reassessment.
• Give pancrelipase with food and preserve the dosage form
  Recognize: Pancrelipase is linked to meals or snacks because it supports digestion of ingested food. Delayed-release forms have administration instructions that protect the medication’s intended action.
  Decide: Give it with the meal or snack as prescribed and follow product-specific directions for swallowing or handling the preparation.
  Avoid: Giving it as a disconnected once-daily drug or crushing a delayed-release preparation without an authorized instruction.
• Connect orlistat effects with dietary adherence
  Recognize: Gastrointestinal changes can occur when fat absorption is reduced, and the patient’s food choices influence tolerability and adherence.
  Decide: Assess the prescribed dietary plan, explain how food choices relate to bowel effects, and review ordered supplementation or follow-up instructions.
  Avoid: Labeling every oily or urgent stool as an emergency, or telling the patient to stop therapy without assessing severity and the prescribed plan.

What to expect on the PNLE

The live inventory supports practice with administration and timing, adverse-effect recognition, medication selection, interaction screening, expected therapeutic response, and priority-care decisions. Stems may ask when to give a drug, which finding requires follow-up, how CKD or warfarin changes the safety review, what improvement to expect with lactulose, or which action comes first in an acute GI presentation.

• Administration items require linking the medicine to meals, snacks, formulation, or the ordered schedule.
• Comparison items ask you to distinguish bowel effects of magnesium- and aluminum-based antacids or separate expected effects from complications.
• Safety items require applying the medication list, CNS-depressant exposure, renal status, and monitoring needs to the patient’s cues.
• Priority items require evaluating assessment findings before selecting a medication-related intervention, including early care decisions in acute pancreatitis.

Difficulty in this 19-question inventory is distributed as 4 easy, 11 medium, and 4 hard questions. Its Bloom distribution is remembering=5, understanding=3, applying=6, and evaluating=5, so practice should progress from retrieving drug facts to applying and evaluating patient-specific evidence. Exact topic distribution varies by exam form; the inventory does not guarantee a microtopic count or predict the composition of a future PNLE.

Study tips

1. Begin with diagnostic practice. Complete a short, mixed set from the 19-question inventory without checking notes. Mark each answer as correct, uncertain, or guessed so your review distinguishes recall gaps from decision-making gaps.
2. Use focused retrieval by medication family. For acid-control, antiemetic, bowel, and hepatic drugs, retrieve the purpose, administration cue, major safety concern, and priority assessment from memory before reopening the rationale.
3. Build a comparison table you can reuse. Draw columns for medication or class, intended effect, key cue, nursing check, and patient teaching. Add rows such as magnesium-based antacid, aluminum-based antacid, H2 blocker, metoclopramide, lactulose, pancrelipase, and orlistat; write the decision rule in your own words.
4. Review every error by cue and action. For each missed or guessed item, record the clinical cue you overlooked, the safest decision, and why the tempting option was weaker. Separate administration errors, interaction errors, adverse-effect errors, and prioritization errors.
5. Retry with spacing, then mix the scope. Reanswer missed items after a delay, again several days later, and during the next review session. Finish with mixed, timed practice that combines acid-control, antiemetic, bowel, and hepatic medication decisions, then compare your reasoning rather than only your score.

Common mistakes to avoid

• Choosing by drug name alone. A familiar acid-control medicine may require a different safety review when CKD, warfarin, or other oral medicines are present. The correcting cue is the complete medication profile plus renal information and the ordered monitoring plan.
• Confusing lactulose’s expected effect with uncontrolled toxicity. Increased bowel elimination can accompany improvement in hepatic encephalopathy, while excessive diarrhea signals a need for hydration, electrolyte, stool-pattern, and mental-status reassessment. Judge the response together with patient tolerance.
• Ignoring meal timing or formulation instructions. Pancrelipase is connected to meals or snacks, and delayed-release preparations should be handled as directed. The safety principle is to verify when and how the product works before administering it.
• Assuming all antiemetic sedation is minor. Metoclopramide combined with CNS depressants can raise concerns about alertness, respiratory safety, and falls; abnormal movements also require attention. Review concurrent medicines and assess the patient before selecting the next action.
• Applying one laxative rule to every bowel problem. A bowel medication choice requires assessment of the underlying condition, pain, distention, hydration, and possible obstruction concerns. Diverticulosis-related constipation questions test assessment and appropriateness, not automatic use of the strongest laxative.
• Teaching orlistat without linking effects to food choices. Gastrointestinal effects can affect adherence and may reflect dietary intake, but severity and persistence still matter. Pair dietary teaching with assessment and the prescribed supplementation or follow-up plan.

Try a question

A real GI & Hepatic Drugs question from our bank. Give it a shot.

More GI & Hepatic Drugs questions

14 questions available. Sign up to practice all of them.

References and further reading

• PRC Enhanced Table of Specifications for the Nurses Licensure Examination official
  The current public competency and cognitive-level blueprint, effective from the November 2025 NLE onward.
• Tangerine Prep PNLE Reviewer question bank
  The live source for the published question count, question previews, rationales, and inventory distributions on this page.

How this page is built

The counts and distributions on this page come from Tangerine Prep's live published question bank. The source inventory was last updated on August 12, 2026.

The questions are original PNLE-style practice items, not recalled or leaked board questions. Topic scope follows Tangerine's pedagogical taxonomy and is mapped to the PRC 2025 Enhanced Table of Specifications, effective from the November 2025 NLE onward. Exact topic distribution varies by exam form.

Related study guides